SGS Life Science Services has expanded its biomarker analytical capabilities with additional modules for its COBAS 6000 analysis system at its Poitiers, France facility. The investment provides biomarker testing capabilities across a number of instrument platforms for both multiplexing and single analyte testing.
 
The Roche COBAS system 6000, installed in June 2014, was initially equipped with the clinical chemistry module for small molecule and analyte testing. The recent expansion adds an immunoassay module that can be used for the quantification of a large number of cytokines, hormones, and other biomarkers of various disease areas such as oncology, endocrinology, sepsis, anemia and cardiac disease.
 
This new module adds further capabilities for drug development supporting biomarkers for various applications, such as risk assessment, safety, and efficacy testing.
  
“It is important for SGS that we continue to adapt and evolve to meet our clients’ needs in this rapidly changing area of the industry,” said Alain Renoux, director of SGS Life Science Services, Poitiers. “By investing in new areas across our global network, both scientifically and geographically, we continue to underpin our commitment to our existing clients and increase our appeal to new markets.”